Fluorescent signs for use in medical devices (Q11207): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Fixing rounding issue)
(‎Removed claim: budget (P474): 421,003.60000000003 euro)
Property / budget
421,003.60000000003 Euro
Amount421,003.60000000003 Euro
UnitEuro
 
Property / budget: 421,003.60000000003 Euro / rank
Preferred rank
 
Property / budget: 421,003.60000000003 Euro / qualifier
exchange rate to Euro: 0.04 Euro
Amount0.04 Euro
UnitEuro
 
Property / budget: 421,003.60000000003 Euro / qualifier
point in time: 10 January 2020
Timestamp+2020-01-10T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 

Revision as of 21:53, 24 September 2020

Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
Fluorescent signs for use in medical devices
Project in Czech Republic financed by DG Regio

    Statements

    0 references
    4,208,983.49 Czech koruna
    0 references
    168,359.34 Euro
    10 January 2020
    0 references
    10,525,090.0 Czech koruna
    0 references
    39.99 percent
    0 references
    20 April 2017
    0 references
    18 April 2020
    0 references
    EXBIO Praha, a.s.
    0 references
    0 references

    49°59'0.49"N, 14°30'9.11"E
    0 references
    25250
    0 references
    Projekt je zaměřen na VaV technologie přípravy specifických fluorescenčních značek, tzv. tandemových fluorochromů, která umožní výrobu skupiny produktů - In vitro diagnostických (IVD) zdravotnických prostředků pro identifikaci maligních, reaktivních a normálních krevních buněk v klinických vzorcích pomocí průtokové cytometrie. Splněním požadavků regulace 21 CFR 820 bude zaručena možnost registrace nových produktů pro klinické aplikace na celosvětových trzích, včetně USA. a. (Czech)
    0 references
    The project is aimed at R & D for the preparation of specific fluorescent marks, so-called tandem fluorochroms, to enable the production of a product group — In vitro diagnostic (IVD) medical devices to identify malignant, reactive and normal blood cells in clinical samples by flow cytometry. Compliance with the requirements of regulation 21 CFR 820 will guarantee the possibility of registering new products for clinical applications in global markets, including USA. a. (English)
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/16_083/0010233
    0 references